Donor immune cells join fight against leukemia in new trial
NCT ID NCT05834244
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 27 times
Summary
This early-phase study tests whether adding healthy donor natural killer (NK) cells to the usual drugs azacitidine and venetoclax can better control acute myeloid leukemia (AML). About 32 adults with AML that has returned or not responded to treatment will receive the combination. The main goal is to check safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Western Reserve University
RECRUITINGCleveland, Ohio, 44106, United States
Contact Email: •••••@•••••
Contact
-
M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.